Tuesday, February 14, 2017

Is this how drug companies should recoup research and development costs?

EpiPen alternative to hit market at more than seven times the price

Pharmaceutical company Kaléo – already under fire for raising the price of an overdose antidote – now plans to put an alternative to the EpiPen on the market for more than seven times the cost of the leading $608 drug.

Kaléo’s epinephrine injector, used to stop severe allergic reactions, will go on sale for $4,500 for a pack of two beginning on 14 February. 

The auto-injector’s innovative audio instructions walk caregivers through administering less than $5 worth of epinephrine.

There has got to be a better way, consistent with private enterprise leading the march in this area, taking risks and reaping rewards.

No comments:

Post a Comment